Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.43 HKD
Change Today -0.08 / -15.69%
Volume 31.3M
As of 4:01 AM 07/3/15 All times are local (Market data is delayed by at least 15 minutes).

extrawell pharmaceutical (858) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/16/15 - $0.73
52 Week Low
03/17/15 - $0.30
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for EXTRAWELL PHARMACEUTICAL (858)

Related News

No related news articles were found.

extrawell pharmaceutical (858) Related Businessweek News

No Related Businessweek News Found

extrawell pharmaceutical (858) Details

Extrawell Pharmaceutical Holdings Limited, an investment holding company, develops, manufactures, and sells pharmaceutical products in the People’s Republic of China. It operates through Manufacturing, Trading, Gene Development, and Oral Insulin segments. The company offers Transfer Factor Oral Solution, a dual immune regulator for the treatment of diseases caused by virus infection and weak cellular immune system; and Wisk for the treatment of II-III degree of radio-injury of skin, normal common burn, actinic dermatitis, various infectious ulcers, and oral ulcers, as well as for trauma and post operation wound healing. It also provides ZhouBang, a thromboxane synthetase inhibitor to prevent the coagulation of platelets and facilitate relaxation of blood vessels; Feining Pian, which is used for the treatment of chronic cough, acute upper respiratory tract infection, infection associated with bronchitis, and emphysema; and YouHuanPing, a sustained-release tablet for sideropenic anemia. In addition, the company is involved in the marketing and distribution of imported pharmaceutical products, including GM-1 to treat lesions of central nervous system due to vascular or traumatic events and Parkinson's disease; Millibar for the treatment of high blood pressure; and Skin-Cap for use in the treatment of psoriasis, dandruff, dermatitis, atopic dermatitis, eczema, and tinea. Further, it is engaged in the commercial exploitation and development of genome-related technology; development and commercialization of oral insulin products; provision of agency services; and property investment business. Extrawell Pharmaceutical Holdings Limited is headquartered in Quarry Bay, Hong Kong.

extrawell pharmaceutical (858) Top Compensated Officers

Chairman, Chief Executive Officer, Chairman o...
Total Annual Compensation: $1.1M
Honorary Chairman and Chief Scientific Adviso...
Total Annual Compensation: $340.0K
Qualified Accountant, Financial Controller, J...
Total Annual Compensation: $275.0K
Executive Director
Total Annual Compensation: $363.0K
Executive Director
Total Annual Compensation: $148.0K
Compensation as of Fiscal Year 2014.

extrawell pharmaceutical (858) Key Developments

Extrawell Pharmaceutical Holdings Ltd. Reports Consolidated Earnings Results for the Year Ended March 31, 2015

Extrawell Pharmaceutical Holdings Ltd. reported consolidated earnings results for the year ended March 31, 2015. For the period, the company reported revenue of HKD 128,833,000 compared to HKD 150,673,000 for the same period a year ago. Loss before taxation was HKD 52,146,000 compared to profit before taxation of HKD 37,349,000 a year ago. Loss for the year from continuing operations was HKD 52,238,000 compared to profit for the year from continuing operations of HKD 16,775,000 a year ago. Profit for the year was HKD 555,305,000 compared to HKD 13,472,000 a year ago. Loss for the year attributable to owners of the company from continuing operations of HKD 44,188,000 compared to profit for the year attributable to owners of the company from continuing operations of HKD 14,123,000 a year ago. Basic and diluted loss per share from continuing operations was HKD 1.85 compared to diluted earnings per share from continuing operations of HKD 0.55 a year ago.

Extrawell Pharmaceutical Holdings Ltd. Provides Earnings Guidance for the Year Ended 31 March 2015

Extrawell Pharmaceutical Holdings Ltd. announced that the Company is in the process of finalizing its annual results for the year ended 31 March 2015. According to the Board's latest assessment and based on the information currently available to it including the Management Accounts and a draft valuation report in respect of the fair value of the Group's investment in an associate, the Company expects further increase in the consolidated profit attributable to equity holders of the Company for the year ended 31 March 2015, which is primarily attributable to, among other things, the non-cash and non-recurring gain on disposal of the Group's 51% equity interest in Smart Ascent Limited, including gain on the fair value of the Group's retained interest in Smart Ascent Limited and fair value changes in the Group's investment in convertible bonds in aggregate of about HKD 550 million.

Extrawell Pharmaceutical Holdings Ltd. to Report Fiscal Year 2015 Results on Jun 29, 2015

Extrawell Pharmaceutical Holdings Ltd. announced that they will report fiscal year 2015 results on Jun 29, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
858:HK $0.43 HKD -0.08

858 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 858.
View Industry Companies

Industry Analysis


Industry Average

Valuation 858 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 1.2x
Price/Cash Flow 2.2x
TEV/Sales 8.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EXTRAWELL PHARMACEUTICAL, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at